Bursa Malaysia Securities Berhad has announced the inclusion of Pharmaniaga Berhad in the PN17 list after the company triggered the criteria of the Main Market Listing Requirements of Bursa Securities
This comes after the group reported a loss for 2022,which it announced in its Bursa filing on 27 February 2023. Bursa adds that it would like to emphasise that it will continue to monitor the progress of PHARMA in respect of its compliance with the Main Market Listing Requirements.
For the year ended 31 December 2022, the Group registered a lower revenue by 27.1% against the previous year as there was lower demand from the government for the purchase of Covid-19 vaccines. The Group posted LBITDA and LBT of RM505.3 million and RM580.8 million respectively in FY2022 decreasing from EBITDA and PBT of RM342.3 million and RM277.1 million respectively in the previous year.
